Urocortin 3 activates AMPK and AKT pathways and enhances glucose disposal in rat skeletal muscle

Journal of Endocrinology

Volumn 223, Issue 2, 2014, Pages 143-154

  Roustit, Manon M ^a   Vaughan, Joan M ^b   Jamieson, Pauline M ^c   Cleasby, Mark E ^a  

^a ROYAL VETERINARY COLLEGE   (United Kingdom)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

AMPK; Glucose disposal; GLUT4; PI3K signalling; Skeletal muscle; Urocortin 3

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENYLATE KINASE; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; PROTEIN KINASE B; SOMATOMEDIN; UROCORTIN III; ONCOPROTEIN; UROCORTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROPORATION; EXTENSOR DIGITORUM LONGUS MUSCLE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; MALE; MUSCLE MASS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; SKELETAL MUSCLE; ANIMAL; AUTOCRINE EFFECT; GENETICS; METABOLISM; MOUSE; PARACRINE SIGNALING; PHYSIOLOGY; SIGNAL TRANSDUCTION; TRANSGENIC RAT; UPREGULATION; WISTAR RAT;

ADENYLATE KINASE; ANIMALS; AUTOCRINE COMMUNICATION; GLUCOSE; MALE; MICE; MUSCLE, SKELETAL; ONCOGENE PROTEIN V-AKT; PARACRINE COMMUNICATION; RATS; RATS, TRANSGENIC; RATS, WISTAR; SIGNAL TRANSDUCTION; UP-REGULATION; UROCORTINS;

EID: 84915745372     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-14-0181     Document Type: Article

References (53)

1. Abo T, Iida RH, Kaneko S, Suga T, Yamada H, Hamada Y & Yamane A 2012 IGF and myostatin pathways are respectively induced during the earlier and the later stages of skeletal muscle hypertrophy induced by clenbuterol, a β(2)-adrenergic agonist. Cell Biochemistry and Function 30 671-676. (doi:10.1002/cbf.2848)
2. Anderson SB, Goldberg AL & Whitman M 2008 Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. Journal of Biological Chemistry 283 7027-7035. (doi:10.1074/jbc.M706678200)
3. Baehr LM, Tunzi M, Bodine SC 2014Muscle hypertrophy is associated with increases inproteasome activitythat is independentofMuRF1 andMAFbx expression. Frontiers in Physiology 5 69. (doi:10.3389/fphys.2014.00069)
4. Bale TL, Anderson KR, Roberts AJ, Lee KF, Nagy TR & Vale WW 2003 Corticotropin-releasing factor receptor-2-deficient mice display abnormal homeostatic responses to challenges of increased dietary fat and cold. Endocrinology 144 2580-2587. (doi:10.1210/en.2002-0091)
5. Bassil MS & Gougeon R 2013 Muscle protein anabolism in type 2 diabetes. Current Opinion in Clinical Nutrition and Metabolic Care 16 83-88. (doi:10.1097/MCO.0b013e32835a88ee)
6. Brar BK, Stephanou A, Knight R & Latchman DS 2002 Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. Journal of Molecular and Cellular Cardiology 34 483-492. (doi:10.1006/jmcc.2002.1529)
7. Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjos OD, Latchman DS, Lee KF & Vale W 2004 Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145 24-35 discussion 21-23. (doi:10.1210/en.2003-0689)
8. Carlin KM, Vale WW & Bale TL 2006 Vital functions of corticotropinreleasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. PNAS 103 3462-3467. (doi:10.1073/pnas. 0511320103)
9. Chan TM & Exton JH 1976 A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes. Analytical Biochemistry 71 96-105. (doi:10.1016/ 0003-2697(76)90014-2)
10. Chanalaris A, Lawrence KM, Townsend PA, Davidson S, Jamshidi Y, Stephanou A, Knight RD, Hsu SY, Hsueh AJ & Latchman DS 2005 Hypertrophic effects of urocortin homologous peptides are mediated via activation of the Akt pathway. Biochemical and Biophysical Research Communications 328 442-448. (doi:10.1016/j.bbrc.2005.01.001)
11. Chao H, Digruccio M, Chen P & Li C 2012 Type 2 corticotropin-releasing factor receptor in the ventromedial nucleus of hypothalamus is critical in regulating feeding and lipid metabolism in white adipose tissue. Endocrinology 153 166-176. (doi:10.1210/en.2011-1312)
12. Chen A, Blount A, Vaughan J, Brar B & Vale W 2004 Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology 145 2445-2457. (doi:10.1210/en.2003-1570)
13. Chen A, Brar B, Choi CS, Rousso D, Vaughan J, Kuperman Y, Kim SN, Donaldson C, Smith SM, Jamieson P et al. 2006 Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. PNAS 103 16580-16585. (doi:10.1073/pnas.0607337103)
14. Chen P, Vaughan J, Donaldson C, Vale W & Li C 2010 Injection of urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis. American Journal of Physiology. Endocrinology and Metabolism 298 E337-E345. (doi:10.1152/ajpendo.00402.2009)
15. CleasbyME, Davey JR, Reinten TA, GrahamMW, James DE, Kraegen EW & Cooney GJ 2005 Acute bidirectional manipulation of muscle glucose uptake byin vivo electrotransferof constructs targeting glucose transporter genes. Diabetes 54 2702-2711. (doi:10.2337/diabetes.54.9.2702)
16. Cleasby ME, Reinten TA, Cooney GJ, James DE & Kraegen EW 2007 Functional studies of Akt isoform specificity in skeletal muscle in vivo; maintained insulin sensitivity despite reduced insulin receptor substrate-1 expression. Molecular Endocrinology 21 215-228. (doi:10.1210/me.2006-0154)
17. Cleasby ME, Jarmin S, Eilers W, Elashry M, Andersen DK, Dickson G & Foster K 2014 Local overexpression of the myostatin propeptide increases glucose transporter expression and enhances skeletal muscle glucose disposal. American Journal of Physiology. Endocrinology and Metabolism 306 E814-E823. (doi:10.1152/ajpendo.00586.2013)
18. Crosson SM, Khan A, Printen J, Pessin JE & Saltiel AR 2003 PTG gene deletion causes impaired glycogen synthesis and developmental insulin resistance. Journal of Clinical Investigation 111 1423-1432. (doi:10.1172/JCI17975)
19. DeFronzo RA & Tripathy D 2009 Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32(Suppl 2) S157-S163. (doi:10.2337/dc09-S302)
20. Di Cola G, Cool MH & Accili D 1997 Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. Journal of Clinical Investigation 99 2538-2544. (doi:10.1172/JCI119438)
21. Hinkle RT, Donnelly E, Cody DB, Bauer MB & Isfort RJ 2003 Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology 144 4939-4946. (doi:10.1210/en.2003-0271)
22. Hsu SY & Hsueh AJ 2001 Human stresscopin and stresscopin-related peptide are selective ligands for the type 2 corticotropin-releasing hormone receptor. Nature Medicine 7 605-611. (doi:10.1038/87936)
23. Jamieson PM, Cleasby ME, Kuperman Y, Morton NM, Kelly PA, Brownstein DG,Mustard KJ, Vaughan JM, Carter RN, Hahn CN et al. 2011 Urocortin 3 transgenic mice exhibit a metabolically favourable phenotype resisting obesity and hyperglycaemia on a high-fat diet. Diabetologia 54 2392-2403. (doi:10.1007/s00125-011-2205-6)
24. Keipert S, Ost M, Johann K, Imber F, Jastroch M, Van Schothorst EM, Keijer J & Klaus S 2013 Skeletal muscle mitochondrial uncoupling drives endocrine cross-talk through induction of FGF21 as a myokine. American Journal of Physiology. Endocrinology and Metabolism 306 E469-E482. (doi:10.1152/ajpendo.00330.2013)
25. Kuizon E, Pearce EG, Bailey SG, Chen-Scarabelli C, Yuan Z, Abounit K, McCauley RB, Saravolatz L, Faggian G, Mazzucco A et al. 2009 Mechanisms of action and clinical implications of cardiac urocortin: a journey from the heart to the systemic circulation, with a stopover in the mitochondria. International Journal of Cardiology 137 189-194. (doi:10.1016/j.ijcard.2009.03.112)
26. Kuperman Y, Issler O, Regev L, Musseri I, Navon I, Neufeld-Cohen A, Gil S & Chen A 2010 Perifornical urocortin-3 mediates the link between stress-induced anxiety and energy homeostasis. PNAS 107 8393-8398. (doi:10.1073/pnas.1003969107)
27. Lantier L, Mounier R, Leclerc J, Pende M, Foretz M & Viollet B 2010 Coordinated maintenance of muscle cell size control by AMP-activated protein kinase. FASEB Journal 24 3555-3561. (doi:10.1096/fj.10-155994)
28. Latres E, Amini AR, Amini AA, Griffiths J, Martin FJ, Wei Y, Lin HC, Yancopoulos GD & Glass DJ 2005 Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. Journal of Biological Chemistry 280 2737-2744. (doi:10.1074/ jbc.M407517200)
29. Lawrence KM, Kabir AM, Bellahcene M, Davidson S, Cao XB, McCormick J, Mesquita RA, Carroll CJ, Chanalaris A, Townsend PA et al. 2005 Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. FASEB Journal 19 831-833. (doi:10.1096/fj.04-2506fje)
30. Lee SJ & McPherron AC 2001 Regulation of myostatin activity and muscle growth. PNAS 98 9306-9311. (doi:10.1073/pnas.151270098)
31. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, FischerWet al. 2001 Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. PNAS 98 7570-7575. (doi:10.1073/pnas.121165198)
32. Li C, Chen P, Vaughan J, Blount A, Chen A, Jamieson PM, Rivier J, Smith MS & Vale W 2003 Urocortin III is expressed in pancreatic β-cells and stimulates insulin and glucagon secretion. Endocrinology 144 3216-3224. (doi:10.1210/en.2002-0087)
33. Li C, Chen P, Vaughan J, Lee KF & Vale W 2007 Urocortin 3 regulates glucose-stimulated insulin secretion and energy homeostasis. PNAS 104 4206-4211. (doi:10.1073/pnas.0611641104)
34. Li J, Qi D, Cheng H, Hu X, Miller EJ, Wu X, Russell KS, Mikush N, Zhang J, Xiao L et al. 2013 Urocortin 2 autocrine/paracrine and pharmacologic effects to activate AMP-activated protein kinase in the heart. PNAS 110 16133-16138. (doi:10.1073/pnas.1312775110)
35. Luo L, Lu AM, Wang Y, Hong A, Chen Y, Hu J, Li X & Qin ZH 2013 Chronic resistance training activates autophagy and reduces apoptosis of muscle cells by modulating IGF-1 and its receptors, Akt/mTOR and Akt/ FOXO3a signaling in aged rats. Experimental Gerontology 48 427-436. (doi:10.1016/j.exger.2013.02.009)
36. Marshall A, Salerno MS, Thomas M, Davies T, Berry C, Dyer K, Bracegirdle J, Watson T, Dziadek M, Kambadur R et al. 2008 Mighty is a novel promyogenic factor in skeletal myogenesis. Experimental Cell Research 314 1013-1029. (doi:10.1016/j.yexcr.2008.01.004)
37. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E et al. 2003 PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics 34 267-273. (doi:10.1038/ng1180)
38. Narici MV & Maffulli N 2010 Sarcopenia: characteristics, mechanisms and functional significance. British Medical Bulletin 95 139-159. (doi:10.1093/bmb/ldq008)
39. Palazzolo I, Stack C, Kong L,Musaro A, Adachi H, KatsunoM, Sobue G, Taylor JP, SumnerCJ, Fischbeck KH et al. 2009Overexpression of IGF-1 inmuscle attenuates disease in a mouse model of spinal and bulbarmuscular atrophy. Neuron 63 316-328. (doi:10.1016/j.neuron.2009.07.019)
40. Patel SA, Hoehn KL, Lawrence RT, Sawbridge L, Talbot NA, Tomsig JL, Turner N, Cooney GJ, Whitehead JP, Kraegen EW et al. 2012 Overexpression of the adiponectin receptor AdipoR1 in rat skeletal muscle amplifies local insulin sensitivity. Endocrinology 153 5231-5246. (doi:10.1210/en.2012-1368)
41. Reutenauer-Patte J, Boittin FX, Patthey-Vuadens O, Ruegg UT & Dorchies OM 2012 Urocortins improve dystrophic skeletal muscle structure and function through both PKA- and Epac-dependent pathways. American Journal of Pathology 180 749-762. (doi:10.1016/j.ajpath.2011.10.038)
42. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW et al. 2001 Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. PNAS 98 2843-2848. (doi:10.1073/pnas.051626398)
43. Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN, Yancopoulos GD & Glass DJ 2001 Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. NatureCell Biology 3 1009-1013. (doi:10.1038/ncb1101-1009)
44. SandriM, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, Goldberg AL & Spiegelman BM 2006 PGC-1a protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. PNAS 103 16260-16265. (doi:10.1073/pnas.0607795103)
45. Solinas G, Summermatter S, Mainieri D, Gubler M, Montani JP, Seydoux J, Smith SR & Dulloo AG 2006 Corticotropin-releasing hormone directly stimulates thermogenesis in skeletal muscle possibly through substrate cycling between de novo lipogenesis and lipid oxidation. Endocrinology 147 31-38. (doi:10.1210/en.2005-1033)
46. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB & Ferrucci L 2008 Sarcopenic obesity: definition, cause and consequences. Current Opinion in Clinical Nutrition and Metabolic Care 11 693-700. (doi:10. 1097/MCO.0b013e328312c37d)
47. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD & Glass DJ 2004 The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Molecular Cell 14 395-403. (doi:10.1016/S1097-2765(04)00211-4)
48. Tsatsanis C, Androulidaki A, Alissafi T, Charalampopoulos I, Dermitzaki E, Roger T, Gravanis A & Margioris AN 2006 Corticotropin-releasing factor and the urocortins induce the expression of TLR4 in macrophages via activation of the transcription factors PU.1 and AP-1. Journal of Immunology 176 1869-1877. (doi:10.4049/jimmunol.176.3.1869)
49. Vaughan JM, Rivier J, Corrigan AZ, McClintock R, Campen CA, Jolley D, Voglmayr JK, Bardin CW, Rivier C & Vale W 1989 Detection and purification of inhibin using antisera generated against synthetic peptide fragments. Methods in Enzymology 168 588-617. (doi:10.1016/ 0076-6879(89)68044-5)
50. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C et al. 1995 Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 287-292. (doi:10.1038/378287a0)
51. Venkatasubramanian S, Griffiths ME, McLean SG, Miller MR, Luo R, Lang NN & Newby DE 2013 Vascular effects of urocortins 2 and 3 in healthy volunteers. Journal of the American Heart Association 2 e004267. (doi:10.1161/JAHA.112.004267)
52. Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S, Lowell B, Scarpulla RC et al. 1999 Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98 115-124. (doi:10.1016/S0092-8674(00) 80611-X)
53. Zheng B, Ohkawa S, Li H, Roberts-Wilson TK & Price SR 2010 FOXO3a mediates signaling crosstalk that coordinates ubiquitin and atrogin-1/MAFbx expression during glucocorticoid-induced skeletal muscle atrophy. FASEB Journal 24 2660-2669. (doi:10.1096/fj.09-151480)